Loading clinical trials...
Loading clinical trials...
Randomized Phase III Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
Conditions
Interventions
Cytarabine
Daunorubicin
+1 more
Locations
62
Austria
Medizinische Universität Graz
Graz, Austria
Tirol Kliniken GmbH Innsbruck
Innsbruck, Austria
Ordensklinikum Linz GmbH, Elisabethinen
Linz, Austria
Feldkirch, Landeskrankenhaus
Rankweil, Austria
Landeskrankenhaus Salzburg
Salzburg, Austria
Hanuschkrankenhaus Wien
Vienna, Austria
Start Date
September 4, 2019
Primary Completion Date
June 1, 2027
Completion Date
June 1, 2027
Last Updated
July 17, 2025
NCT06285890
NCT06220162
NCT04065399
NCT06484062
NCT04628026
NCT06994676
Lead Sponsor
University of Ulm
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions